Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK
- 21 March 2024
- journal article
- review article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 24 (9) , e576-e583
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in EnglandJournal of Infection, 2023
- Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic reviewVaccine, 2023
- 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementationJournal of Infection, 2023
- The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccinationJournal of Infection, 2020
- Testing for gonorrhoea should routinely include the pharynxThe Lancet Infectious Diseases, 2018
- Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control studyThe Lancet, 2017
- Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort studyThe Lancet, 2016
- The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme – New challenges for public healthJournal of Infection, 2015
- MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccineVaccine, 2015
- Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccinesVaccine, 2012